Estados financieros detallados de Amylyx Pharmaceuticals, Inc. (AMLX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $1.4M | $650000 | 0 | $22.2M | $380.8M | $87.4M | 0 |
| Coste de Ventas | $11.9M | $24.6M | 0 | $3.0M | $25.4M | $42.2M | $525000 |
| Beneficio Bruto | -$10.5M | -$23.9M | 0 | $19.2M | $355.3M | $45.2M | -$525000 |
| I+D | $11.9M | $24.6M | $44.0M | $93.5M | $128.2M | $104.1M | $90.4M |
| Generales y Administrativos | $3.1M | $15.1M | $38.9M | $127.1M | $188.4M | $114.3M | $62.9M |
| Gastos Operativos | $13.6M | $15.1M | $82.7M | $220.6M | $316.5M | $359.9M | $152.8M |
| Beneficio Operativo | -$13.6M | -$39.0M | -$82.7M | -$201.3M | $38.8M | -$314.7M | -$153.3M |
| EBITDA | $1.1M | -$39.0M | -$87.9M | -$197.1M | $55.4M | -$291.0M | -$144.2M |
| Gastos por Intereses | $1.3M | $2.3M | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$13.7M | -$42.3M | -$87.9M | -$197.6M | $54.3M | -$302.1M | -$144.7M |
| Impuestos | 0 | 0 | 0 | $774000 | $5.0M | -$393000 | $46000 |
| Beneficio Neto | -$14.8M | -$42.3M | -$87.9M | -$198.4M | $49.3M | -$301.7M | -$144.7M |
| BPA | $-0.26 | $-0.79 | $-1.52 | $-2.98 | $0.73 | $-4.43 | $-1.53 |
| BPA Diluido | $-0.26 | $-0.79 | $-1.52 | $-2.98 | $0.70 | $-4.43 | $-1.53 |
| Acciones en Circulación (Diluidas) | $56.5M | $56.5M | $57.9M | $66.5M | $70.0M | $68.1M | $94.6M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$19.9M | -$108000 | -$98000 | 0 |
| Beneficio Operativo | -$36.0M | -$36.6M | -$43.8M | -$45.7M |
| EBITDA | -$34.3M | -$30.9M | -$41.2M | -$43.4M |
| Beneficio Neto | -$34.4M | -$33.0M | -$41.3M | -$43.4M |
| BPA | $-0.37 | $-0.28 | $-0.37 | $-0.39 |
| BPA Diluido | $-0.37 | $-0.28 | $-0.37 | $-0.39 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $3.1M | $12.9M | $50.2M | $62.5M | $170.2M | $77.4M | $226.7M |
| Inversiones a Corto | 0 | 0 | $45.9M | $284.4M | $201.2M | $99.1M | $90.3M |
| Cuentas por Cobrar | 0 | 0 | 0 | $15.3M | $40.0M | $447000 | $88000 |
| Inventario | 0 | 0 | 0 | $9.8M | $38.3M | 0 | 0 |
| Activos Corrientes | $3.2M | $13.6M | $105.0M | $382.1M | $464.7M | $189.4M | $323.7M |
| Inmovilizado Material | 0 | $151000 | $474000 | $8.1M | $6.4M | $2.7M | $5.5M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $3.2M | $14.1M | $105.6M | $391.5M | $517.5M | $193.6M | $332.6M |
| Cuentas por Pagar | $2.2M | $3.6M | $4.4M | $6.3M | $22.1M | $2.9M | $3.5M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $4.5M | $7.3M | $17.4M | $46.6M | $82.0M | $28.4M | $22.7M |
| Deuda a Largo | $14.9M | $1.4M | 0 | 0 | 0 | 0 | $4.7M |
| Pasivos Totales | $28.6M | $80.8M | $256.8M | $50.8M | $84.0M | $28.9M | $27.4M |
| Reservas | -$25.6M | -$67.9M | -$155.8M | -$354.2M | -$304.9M | -$606.7M | -$751.4M |
| Patrimonio Neto | -$25.4M | -$66.7M | -$151.2M | $340.6M | $433.4M | $164.8M | $305.3M |
| Deuda Total | $14.9M | $1.4M | 0 | $6.3M | $4.2M | $2.0M | $6.0M |
| Deuda Neta | $11.9M | -$11.5M | -$96.1M | -$340.7M | -$367.1M | -$174.5M | -$311.0M |
| Capital Circulante | -$1.3M | $6.3M | $87.6M | $335.5M | $382.6M | $161.0M | $301.0M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $225.2M | $226.7M | $229.1M | $49.3M |
| Activos Totales | $362.7M | $332.6M | $293.6M | $264.6M |
| Pasivos Totales | $30.7M | $27.4M | $20.4M | $25.4M |
| Patrimonio Neto | $332.0M | $305.3M | $273.2M | $239.2M |
| Deuda Total | $5.9M | $6.0M | $5.6M | $5.3M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$13.7M | -$42.3M | -$87.9M | -$198.4M | $49.3M | -$301.7M | -$144.7M |
| Amortizaciones | 0 | $1000 | $52000 | $487000 | $1.1M | $904000 | $525000 |
| Compensación en Acciones | $108000 | $243000 | $3.1M | $21.7M | $37.2M | $33.0M | $27.6M |
| Cambio en Capital Circulante | $3.5M | $2.6M | $4.6M | -$1.6M | -$65.7M | -$45.8M | -$1.1M |
| Flujo de Caja Operativo | -$10.7M | -$36.7M | -$74.8M | -$179.9M | $11.9M | -$167.6M | -$123.3M |
| Inversiones (CapEx) | 0 | -$151000 | -$353000 | -$2.5M | -$1.2M | -$157000 | -$138000 |
| Adquisiciones | 0 | 0 | 0 | $236.5M | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$10.7M | -$36.8M | -$75.2M | -$182.4M | $10.7M | -$167.8M | -$123.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$30.4M | -$27.9M | -$36.9M | -$31.4M |
| Inversiones (CapEx) | -$24000 | -$86000 | 0 | -$30000 |
| Flujo de Caja Libre | -$30.4M | -$28.0M | -$36.9M | -$31.5M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $7.1M | $6.4M | $6.1M | $8.3M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | -54.4% | -100.0% | | +1612.9% | -77.1% | -100.0% |
| Crecimiento Beneficio Neto (anual) | | -185.4% | -108.0% | -125.6% | +124.8% | -712.4% | +52.0% |
| Crecimiento BPA (anual) | | -203.8% | -92.4% | -96.1% | +124.5% | -706.8% | +65.5% |
| Cambio en Acciones (anual) | | +0.0% | +2.5% | +14.9% | +5.2% | -2.6% | +38.8% |
| Crecimiento FCF (anual) | | -244.8% | -104.0% | -142.7% | +105.9% | -1671.5% | +26.4% |
| Margen Bruto | -734.4% | -3683.7% | | 86.5% | 93.3% | 51.8% | |
| Margen Operativo | -950.5% | -6000.8% | | -905.7% | 10.2% | -360.2% | |
| Margen EBITDA | 78.1% | -6000.6% | | -886.7% | 14.5% | -333.0% | |
| Margen Neto | -1039.0% | -6504.6% | | -892.4% | 12.9% | -345.4% | |
| Margen FCF | -749.4% | -5668.9% | | -820.5% | 2.8% | -192.1% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.4% | 9.3% | 0.1% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.19 | $-0.65 | $-1.30 | $-2.74 | $0.15 | $-2.46 | $-1.31 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $56.5M | $56.5M | $57.9M | $66.5M | $67.2M | $68.1M | $94.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -69.50 | -22.87 | -11.89 | -12.40 | 20.16 | -0.85 | -7.90 |
| P/VC | -40.24 | -15.29 | -6.92 | 7.22 | 2.28 | 1.56 | 3.74 |
| P/V | 715.53 | 1569.76 | 0.00 | 110.55 | 2.60 | 2.95 | 0.00 |
| Margen Bruto | -734.4% | -3683.7% | 0.0% | 86.5% | 93.3% | 51.8% | 0.0% |
| Margen Operativo | -950.5% | -6000.8% | 0.0% | -905.7% | 10.2% | -360.2% | 0.0% |
| Margen Neto | -1039.0% | -6504.6% | 0.0% | -892.4% | 12.9% | -345.4% | 0.0% |